GAF Healthcare
Specialty Overview

Best Hospitals for Crohn's Disease Treatment in India

90 surgical gastroenterology hospitals in our India network are listed, across 5 cities (Mumbai, Delhi NCR, Bengaluru, Hyderabad, Chennai), accredited by JCI, NABH, ISO, NABL, with 51,822 beds combined.

90
Hospitals Listed
5
Cities
4.5
Avg. Rating
5
Accreditation Types
The Short Answer

This page lists the surgical gastroenterology hospitals in our directory offering Crohn's Disease Treatment in India, including Nanavati Super Specialty Hospital, Apollo Hospitals, Medanta - The Medicity, Artemis Hospital and others. Hospitals are listed across Mumbai, Delhi NCR, Bengaluru, Hyderabad, Chennai. Each listing links through to the hospital's full profile page.

Including:🇮🇳 Nanavati Super Specialty Hospital🇮🇳 Apollo Hospitals🇮🇳 Medanta - The Medicity

Ask us about crohn's disease treatment in India

Share a few details and our care coordination team will get back to you with next steps.

Compare 90 accredited hospitals for Surgical Gastroenterology in India

Nanavati Super Specialty Hospital Featured

🇮🇳 Nanavati Super Specialty Hospital

Mumbai, India 5 (12 reviews) 350 beds
Why consider this hospital?
5/5 rating from 12 reviewsAccredited by JCI, NABH350 beds
Specialties & Accreditation
OncologyCardiac SurgeryNeurosciencesTransplantBariatrics
Accredited by JCI, NABH
5/5
Rating
1950
Established
350
Beds
Mumbai, India
Location
Enquire NowView Profile
Apollo Hospitals

🇮🇳 Apollo Hospitals

New Delhi, India 4.9 (1240 reviews) 1,000 beds
Why consider this hospital?
4.9/5 rating from 1240 reviewsAccredited by JCI, NABH1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH
4.9/5
Rating
1983
Established
1,000
Beds
New Delhi, India
Location
Enquire NowView Profile
Medanta - The Medicity

🇮🇳 Medanta - The Medicity

Gurgaon, India 4.9 (2150 reviews) 1,600 beds
Why consider this hospital?
4.9/5 rating from 2150 reviewsAccredited by JCI, NABH1,600 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH
4.9/5
Rating
2009
Established
1,600
Beds
Gurgaon, India
Location
Enquire NowView Profile
Artemis Hospital

🇮🇳 Artemis Hospital

Gurgaon, India 4.9 (64 reviews) 750 beds
Why consider this hospital?
4.9/5 rating from 64 reviewsAccredited by JCI, NABH750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH
4.9/5
Rating
2007
Established
750
Beds
Gurgaon, India
Location
Enquire NowView Profile
Fortis Memorial Research Institute

🇮🇳 Fortis Memorial Research Institute

Gurgaon, India 4.8 (1100 reviews) 1,000 beds
Why consider this hospital?
4.8/5 rating from 1100 reviewsAccredited by JCI, NABH1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
Accredited by JCI, NABH
4.8/5
Rating
1996
Established
1,000
Beds
Gurgaon, India
Location
Enquire NowView Profile
Kokilaben Dhirubhai Ambani Hospital

🇮🇳 Kokilaben Dhirubhai Ambani Hospital

Mumbai, India 4.8 (1800 reviews) 750 beds
Why consider this hospital?
4.8/5 rating from 1800 reviewsAccredited by JCI, NABH750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
Accredited by JCI, NABH
4.8/5
Rating
2009
Established
750
Beds
Mumbai, India
Location
Enquire NowView Profile
Tata Memorial Hospital

🇮🇳 Tata Memorial Hospital

Mumbai, India 4.8 (2500 reviews) 629 beds
Why consider this hospital?
4.8/5 rating from 2500 reviewsAccredited by NABH629 beds
Specialties & Accreditation
OncologyCancer Center
Accredited by NABH
4.8/5
Rating
1941
Established
629
Beds
Mumbai, India
Location
Enquire NowView Profile
Max Super Specialty Hospital

🇮🇳 Max Super Specialty Hospital

New Delhi, India 4.8 (1300 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 1300 reviewsAccredited by JCI, NABH500 beds
Specialties & Accreditation
CardiacLiver Transplant
Accredited by JCI, NABH
4.8/5
Rating
2000
Established
500
Beds
New Delhi, India
Location
Enquire NowView Profile
Narayana Health

🇮🇳 Narayana Health

Bengaluru, India 4.8 (1750 reviews) 1,000 beds
Why consider this hospital?
4.8/5 rating from 1750 reviewsAccredited by NABH1,000 beds
Specialties & Accreditation
CardiacPediatric SurgeryCancer
Accredited by NABH
4.8/5
Rating
2000
Established
1,000
Beds
Bengaluru, India
Location
Enquire NowView Profile
Yashoda Hospitals, Hi-Tech City

🇮🇳 Yashoda Hospitals, Hi-Tech City

Hi-Tech City, Hyderabad, India 4.8 (742 reviews) 2,000 beds
Why consider this hospital?
4.8/5 rating from 742 reviewsAccredited by JCI, NABH2,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyOncologyNeurologyOrthopedicsOrgan Transplant
Accredited by JCI, NABH
4.8/5
Rating
1989
Established
2,000
Beds
Hi-Tech City, Hyderabad, India
Location
Enquire NowView Profile
Our Methodology

How we selected these hospitals

A hospital appears on this page when Surgical Gastroenterology is among its listed specialties and it is located in India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Crohn's Disease Treatment in India?

Choosing the right hospital for crohn's disease treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include surgical gastroenterology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Crohn's Disease Treatment

Crohn's disease is a chronic, relapsing inflammatory bowel disease (IBD) requiring lifelong, individualized management ranging from advanced biologic therapies and small-molecule immunomodulators to precision laparoscopic or robotic-assisted intestinal surgery. International patients achieve remission rates exceeding 70–85% with biologic induction protocols and over 90% short-term surgical success rates at leading accredited centers. GAF Healthcare connects patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed facilities in Dubai and Abu Dhabi, offering world-class gastroenterology and colorectal surgery at a fraction of Western costs, with end-to-end coordination from visa assistance to post-discharge follow-up.

5–14 days (medical flare management: 5–7 days; elective bowel resection: 7–14 days)
Hospital Stay
2–6 weeks (biologic infusion/medical management: 2–3 weeks; open or laparoscopic bowel surgery: 4–6 weeks)
Total Stay in Country (Fit-to-Fly)
70–85% sustained clinical remission with biologic therapy; 90–95% short-term surgical success for resection
Success Rate

Clinical Overview

Crohn's disease is a transmural, granulomatous inflammatory bowel disease that can affect any segment of the gastrointestinal tract from the mouth to the perianal region, most commonly involving the terminal ileum and proximal colon. Unlike ulcerative colitis, which is confined to the colonic mucosa, Crohn's inflammation penetrates all layers of the bowel wall, predisposing patients to fibrotic strictures, internal fistulae, intra-abdominal abscesses, and perianal septic complications. Disease behavior is classified using the Montreal Classification into inflammatory (B1), stricturing (B2), and penetrating (B3) phenotypes, with perianal disease designated separately (p). The heterogeneous nature of the disease demands individualized phenotype-driven treatment strategies.

Full details →

Who is a Candidate?

  • ELIGIBLE PATIENTS:
  • Adults and adolescents (age ≥ 6 years under pediatric protocols) with confirmed Crohn's disease diagnosis based on endoscopic, histopathological, and cross-sectional imaging criteria
  • Patients with moderate-to-severe active disease defined by CDAI ≥ 220, HBI ≥ 8, or elevated fecal calprotectin (> 250 µg/g) with concurrent mucosal inflammation on endoscopy
  • Patients failing or intolerant to conventional therapy (corticosteroids, azathioprine, 6-MP, methotrexate) who are candidates for biologic or small-molecule (JAK inhibitor: upadacitinib) induction
  • Patients with steroid-dependent or steroid-refractory disease requiring biologic optimization or combination immunosuppression
  • +25 more

Treatment Options & Approaches

Medical (non-surgical) THERAPIES:

1. Induction and Maintenance with Biologic Agents:

  • Anti-TNF Monoclonal Antibodies: Infliximab (IV infusion: 5 mg/kg at weeks 0, 2, 6, then every 8 weeks) and Adalimumab (SC injection: 160/80/40 mg induction, then 40 mg every 2 weeks) are first-line biologics for moderate-to-severe Crohn's. Combination with azathioprine (2.0–2.5 mg/kg/day) reduces immunogenicity and improves sustained remission rates (SONIC trial data: 56.8% corticosteroid-free remission with combination vs. 44.4% infliximab monotherapy at week 26). Therapeutic drug monitoring (TDM) of trough levels (infliximab target: > 3–7 µg/mL in maintenance) is now standard practice at high-quality IBD centers.
  • Anti-Integrin Therapy (Vedolizumab): A gut-selective α4β7 integrin antagonist (IV: 300 mg at weeks 0, 2, 6, then every 8 weeks) with a superior safety profile. Preferred for patients with prior malignancy, demyelinating disease, or recurrent infections. Onset is slower (peak response at 14 weeks); optimal for maintenance in biologic-naive moderate disease.
  • Anti-IL-12/23 (Ustekinumab): IV weight-based induction dose (~6 mg/kg), followed by SC 90 mg every 8–12 weeks. Highly effective in anti-TNF–experienced patients (UNIFI/IM-UNIFI data). Excellent safety profile; preferred in older patients or those with recurrent infections.
  • JAK Inhibitors (Small Molecules): Upadacitinib (Rinvoq, 45 mg once daily induction for 12 weeks, then 30 mg or 15 mg maintenance) received FDA approval for moderate-to-severe Crohn's disease in 2023. Oral administration offers convenience. Monitoring required for lipid profile, CBC, and cardiovascular risk factors. Not recommended in patients > 65 years or with high cardiovascular risk.

2. Immunomodulators:

Full details →

Recovery

PHASE 1 — PRE-ARRIVAL PREPARATION (4–6 weeks before travel):

  • Step 1: Submit medical records to GAF Healthcare (previous endoscopy reports, biopsy histopathology, MR enterography/CT enterography, operative notes if prior surgery, current medication list including biologic therapy details and TDM levels).
  • Step 2: GAF Healthcare medical team conducts virtual tele-consultation with the treating gastroenterologist or colorectal surgeon in India or UAE. A personalized treatment plan is formulated (biologic optimization vs. surgical intervention).
  • Step 3: Nutritional optimization initiated if pre-operative malnutrition is identified (serum albumin < 30 g/L): enteral nutrition support prescribed for 4–6 weeks; parenteral nutrition reserved for those with obstructing strictures.
  • Step 4: Latent TB treatment initiated if QuantiFERON Gold positive (minimum 4 weeks of isoniazid before starting anti-TNF therapy).
  • Step 5: Visa arrangement — Indian e-Medical Visa application submitted by GAF Healthcare with hospital invitation letter; UAE patients receive visa-on-arrival or e-Visa arranged by GAF team.
  • Step 6: Biologic therapy bridging — for patients mid-course, scheduling of infusion (infliximab) or injection (adalimumab/ustekinumab) timed to coincide with hospital arrival.

PHASE 2 — ARRIVAL AND ADMISSION (Day 0–2):

Full details →

Risks to be aware of

Crohn's disease treatment carries procedure-specific and disease-specific risks that must be transparently communicated to international patients. For biologic therapy, the primary risks include serious infections (bacterial, viral reactivation of TB or hepatitis B, opportunistic fungal infections such as Pneumocystis jirovecii pneumonia in patients on triple immunosuppression), infusion-related or injection-site reactions (anaphylaxis incidence < 1% with infliximab), and a statistically elevated but absolute-risk-small increase in lymphoma (primarily hepatosplenic T-cell lymphoma with prolonged thiopurine use in young males) and non-melanoma skin cancer. JAK inhibitors (upadacitinib) carry additional class-specific risks including thromboembolism (deep vein thrombosis, pulmonary embolism, particularly at higher doses), major adverse cardiovascular events (MACE) in patients with pre-existing cardiovascular risk factors, and secondary malignancies; these risks necessitate careful patient selection per FDA and EMA label restrictions. For surgical patients, the major risks include anastomotic leak (incidence 2–7% for ileocolic anastomosis; higher in malnourished or steroid-exposed patients), intra-abdominal abscess requiring percutaneous drainage or re-operation, small bowel obstruction (adhesional), wound infection (laparotomy wound infection rate 10–15%; laparoscopic wounds significantly lower at 2–4%), and stoma-related complications (retraction, prolapse, parastomal hernia). Disease-specific surgical risks include short bowel syndrome if cumulative resected small bowel length exceeds 100–150 cm, fistula recurrence following resection (endoscopic recurrence at 6 months in up to 65–90% without prophylactic post-operative biologic therapy, mandating routine post-operative Rutgeerts scoring and early biologic reinstitution). Venous thromboembolism risk is inherently elevated in active IBD and perioperative periods; pharmacological (LMWH) and mechanical (graduated compression stockings) prophylaxis is non-negotiable throughout the hospital stay and for 28 days following major abdominal surgery. International patients must disclose their complete medical history, current medications (including NSAIDs which may precipitate Crohn's flares), and arrange adequate travel insurance covering emergency re-intervention before undertaking medical travel for this condition.

Why GAF Healthcare

GAF Healthcare provides a fully integrated, end-to-end coordination service for international Crohn's disease patients traveling to India or the UAE, removing the logistical burden from patients managing a complex chronic illness.

Common questions about Crohn's Disease Treatment

What is the cost of Crohn's Disease Treatment in India versus the UAE?
The total cost of Crohn's disease treatment depends significantly on the modality required. For biologic therapy induction (e.g., infliximab infusion at weeks 0, 2, and 6 with hospitalization and monitoring), costs in India range from approximately USD 3,500 to USD 8,000 for the initial three-infusion induction cycle including diagnostics and hospital stay, compared to USD 7,000 to USD 15,000 for the equivalent protocol in Dubai or Abu Dhabi. For surgical intervention — such as laparoscopic ileocecal resection with pre-operative workup, operating theatre, 7–10 days of hospitalization, anesthesia, pathology, and standard post-operative medications — the all-inclusive cost in India ranges from USD 6,000 to USD 18,000 depending on surgical complexity, hospital tier (NABH vs. JCI), and city. In the UAE, equivalent surgical packages range from USD 14,000 to USD 35,000. Complex perianal Crohn's surgery (VAAFT, seton, advancement flap) adds USD 1,500–USD 4,000 to surgical estimates in India and USD 3,000–USD 8,000 in the UAE. India is typically 50–65% less expensive than the UAE for the same standard of care, and both destinations represent substantial savings versus Western Europe (USD 40,000–USD 80,000) or the United States (USD 60,000–USD 150,000+ for major bowel resection). Biologic drug costs (adalimumab, ustekinumab, vedolizumab) are invoiced separately and vary by agent; Indian biosimilar availability significantly reduces ongoing maintenance therapy costs. GAF Healthcare provides a fully itemized cost estimate upon review of patient records, with no hidden fees.
How long do I need to stay in the country before I am fit to fly home?
The minimum required in-country stay before safe international air travel depends on the treatment pathway. For patients undergoing biologic induction therapy (infliximab IV infusion series or ustekinumab weight-based IV induction), the minimum recommended stay is 2–3 weeks: this covers the infusion itself, a 24-hour post-infusion observation period, and a 2-week recovery interval to assess for delayed infusion reactions, early clinical response, and to ensure oral maintenance therapy (azathioprine, self-injectable biologic) is stable and tolerated before the patient boards a long-haul flight. For patients undergoing elective laparoscopic or robotic-assisted bowel resection (e.g., ileocecal resection, segmental colectomy, strictureplasty), the fit-to-fly period is 4–6 weeks post-surgery. This timeline is determined by the need for wound healing confirmation, anastomotic integrity surveillance (clinical and biochemical), stoma stabilization and output predictability (if a diverting ileostomy was formed), and safe tapering of post-operative VTE prophylaxis (LMWH typically continues for 28 days after major abdominal surgery). Air travel during the early post-operative period carries elevated deep vein thrombosis and pulmonary embolism risk in IBD patients, and cabin pressurization may exacerbate abdominal bloating. For flights exceeding 4 hours, even after clearance, GAF Healthcare arranges a fit-to-fly medical certificate, travel compression stockings, and coordinates a pre-flight LMWH dose with your treating team. Patients with stomas are provided with adequate stoma supplies for the journey and a letter for airport security. All fit-to-fly decisions are made by the treating surgeon or gastroenterologist based on individual clinical assessment, not solely on the above timelines.
What is the success rate of Crohn's Disease Treatment?
Success rates in Crohn's disease must be defined by the treatment modality and the specific endpoint measured, as Crohn's is a chronic relapsing condition without a definitive cure. For biologic induction therapy with anti-TNF agents (infliximab or adalimumab), clinical remission rates at 12 months are approximately 38–58% in anti-TNF-naive patients (ACCENT I, CHARM trial data), with corticosteroid-free remission in combination therapy (anti-TNF + thiopurine) approaching 57% at 26 weeks (SONIC trial). Ustekinumab achieves clinical remission in approximately 40–53% at 44 weeks in biologic-naive and anti-TNF-experienced patients respectively (UNIFI extension data). Mucosal healing — the gold-standard T2T endpoint — is achieved in 30–50% of patients after 1 year of optimized biologic therapy with therapeutic drug monitoring. For surgical intervention, short-term success (technically successful resection with primary anastomosis, absence of major complications) is achieved in over 90–95% of cases at high-volume IBD surgical centres. However, Crohn's disease recurs at the surgical site: endoscopic recurrence at the neo-terminal ileum (Rutgeerts score i2–i4) occurs in 65–90% of patients within 12 months of ileocecal resection without post-operative prophylactic biologic therapy. With immediate post-operative biologic reinstitution (infliximab or adalimumab within 4 weeks of surgery), endoscopic recurrence rates at 12 months are reduced to 9–23% (PREVENT trial, POCER trial). The 10-year cumulative surgical re-operation rate is approximately 30–40% overall, highlighting the critical importance of long-term mucosal healing surveillance and proactive biologic optimization. GAF Healthcare partner centres apply standardized post-operative Rutgeerts scoring at 6 months and mandatory biologic prophylaxis protocols to maximize long-term durable remission for international patients.

Related pages

How GAF Healthcare Assists in Choosing the Best Hospital for Crohn's Disease Treatment in India

Discover the Top Hospitals for Crohn's Disease Treatment in India

This page lists 90 accredited surgical gastroenterology hospitals in India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about crohn's disease treatment in India

How many surgical gastroenterology hospitals are listed in India?
90 hospitals in our India directory are currently listed for surgical gastroenterology including Crohn's Disease Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Surgical Gastroenterology is among its listed specialties and it is located in India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Which cities in India have surgical gastroenterology hospitals listed?
Mumbai, Delhi NCR, Bengaluru, Hyderabad, Chennai. Use the city links on this page to view hospitals in a specific city.
🤔

Still have questions?

Our coordinators are here to answer your questions about crohn's disease treatment in India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for crohn's disease treatment in India.

Contact us to report an inaccuracy on this page.

WhatsApp Us